Advertisement

Topics

FDA advisers reject J&J rheumatoid arthritis drug

07:47 EDT 3 Aug 2017 | pharmaphorum

The chances of Johnson & Johnson’s rheumatoid arthritis drug sirukumab getting approved in the US look slim, after the FDA’s expert advisers raised concerns about its safety. The regulator’s Arthritis Advisory Committee voted 12 to 1 aga...

Original Article: FDA advisers reject J&J rheumatoid arthritis drug

NEXT ARTICLE

More From BioPortfolio on "FDA advisers reject J&J rheumatoid arthritis drug"

Quick Search
Advertisement
 

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...